Table Graph
      published meta-analysis   sensitivity analysis   studies

umifenovir (arbidol) in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias clinical deteriorationdetailed resultsELACOI (Standard of care), 2020 0.86 [0.06; 11.36] 0.86[0.06; 11.36]ELACOI (Standard of care), 202010%23NAnot evaluable radiologic improvement (14-day)detailed resultsELACOI (Standard of care), 2020 0.18 [0.01; 3.99] 0.18[0.01; 3.99]ELACOI (Standard of care), 202010%21NAnot evaluable radiologic improvement (7-day)detailed resultsELACOI (Standard of care), 2020 0.08 [0.00; 1.71] 0.08[0.00; 1.71]ELACOI (Standard of care), 202010%21NAnot evaluable viral clearance detailed resultsELACOI (Standard of care), 2020 2.80 [0.31; 25.53] 2.80[0.31; 25.53]ELACOI (Standard of care), 202010%23NAnot evaluable viral clearance by day 14detailed resultsELACOI (Standard of care), 2020 2.80 [0.31; 25.53] 2.80[0.31; 25.53]ELACOI (Standard of care), 202010%23NAnot evaluable viral clearance by day 7detailed resultsELACOI (Standard of care), 2020 0.67 [0.10; 4.58] 0.67[0.10; 4.58]ELACOI (Standard of care), 202010%23NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-04-19 23:03 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 516 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons